Hybrid TiO2 -Ruthenium Nano-photosensitizer Synergistically Produces Reactive Oxygen Species in both Hypoxic and Normoxic Conditions

Angew Chem Int Ed Engl. 2017 Aug 28;56(36):10717-10720. doi: 10.1002/anie.201704458. Epub 2017 Jul 26.

Abstract

Photodynamic therapy (PDT) is widely used to treat diverse diseases, but its dependence on oxygen to produce cytotoxic reactive oxygen species (ROS) diminishes the therapeutic effect in a hypoxic environment, such as solid tumors. Herein, we developed a ROS-producing hybrid nanoparticle-based photosensitizer capable of maintaining high levels of ROS under both normoxic and hypoxic conditions. Conjugation of a ruthenium complex (N3) to a TiO2 nanoparticle afforded TiO2 -N3. Upon exposure of TiO2 -N3 to light, the N3 injected electrons into TiO2 to produce three- and four-fold more hydroxyl radicals and hydrogen peroxide, respectively, than TiO2 at 160 mmHg. TiO2 -N3 maintained three-fold higher hydroxyl radicals than TiO2 under hypoxic conditions via N3-facilitated electron-hole reduction of adsorbed water molecules. The incorporation of N3 transformed TiO2 from a dual type I and II PDT agent to a predominantly type I photosensitizer, irrespective of the oxygen content.

Keywords: TiO2; nanophotosensitizer; photodynamic therapy; reactive oxygen species (ROS); ruthenium complexes.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Hypoxia / drug therapy*
  • Nanoparticles / chemistry*
  • Photochemotherapy
  • Photosensitizing Agents / chemistry
  • Photosensitizing Agents / pharmacology*
  • Reactive Oxygen Species / metabolism*
  • Ruthenium / chemistry
  • Ruthenium / pharmacology*
  • Titanium / chemistry
  • Titanium / pharmacology*

Substances

  • Photosensitizing Agents
  • Reactive Oxygen Species
  • titanium dioxide
  • Ruthenium
  • Titanium